,9 So far, acquired resistance has not been systematically explored in first line setting in NSCLC patients enrolled in clinical trials, and the role of PCT or CTLA-4 inhibitors in influencing acquired resistance upon PD-1/PD-L1 is currently unknown. The gene discussed is CD274; the disease is non-small cell lung carcinoma.